Astellas Pharma

China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere. China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to…

BEIJING—Hiroshi Nishiyama, a veteran Japanese executive at Astellas Pharma Inc. and a prominent member of his country’s business circle in China, spent late March wrapping up his assignment there and preparing to head home. He never made it. Mr. Nishiyama disappeared on what was supposed to be his last day in China. A few days later, China’s Foreign Ministry said he had been accused of espionage and detained. BEIJING—Hiroshi Nishiyama, a veteran Japanese executive at Astellas Pharma…

Surprise visits, probes and detentions come just months after Beijing’s open-for-business message to global investors. Surprise visits, probes and detentions come just months after Beijing’s open-for-business message to global investors. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials…

HONG KONG—Chinese authorities have arrested an employee of Japanese drugmaker Astellas Pharma Inc., ALPMY 0.38% the second detention of foreign company staff to have surfaced in recent days and when Beijing is seeking to reassure the business community of its commitment to an open policy. China informed the Japanese Embassy that one of its nationals, a man in his 50s, had been detained in Beijing, Japan’s chief spokesman…

An unprofitable biotech that pioneered a relatively new kind of cancer therapy has caught the attention of the world’s largest drugmakers on the hunt for the next big opportunity in one of the industry’s most lucrative markets.  Seagen Inc. sells three of the novel cancer agents—known as antibody drug conjugates, or ADCs—that work like a guided missile attacking tumors with toxins. Although the company’s products generate around $2 billion in yearly sales and the company operates at a loss,…